SNGX News and Press, Soligenix Inc. From 12/22/20

Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients Company to Host Investor Conference Call Today at 8:30AM EST PR Newswire PRINCETON, N.J. , Dec. 22, 2020 /PRNews...

Soligenix ([[SNGX]] +7.3%) has entered into a $20M convertible debt financing agreement with Pontifax Medison Debt Financing, the healthcare-dedicated venture and debt fund of the Pontifax life science funds.Soligenix to have access to up to $20M in convertible debt financing in three tranche...

Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing PRINCETON, N.J. , Dec. 16, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focu...

Soligenix Demonstrates Extended Protection with its RiVax® Ricin Toxin Vaccine PRINCETON, N.J. , Dec. 8, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and com...

Why Are These Top Penny Stocks Attracting Attention? Investing in penny stocks is all about being ahead of the game. While this is not always the case, it often pays to stay up to date with the happenings of the stock market. This means following news events as well as trajectories ...

New York, New York--(Newsfile Corp. - November 17, 2020) - Enthusiasm is surrounding Pfizer's and Moderna's announcement of COVID-19 vaccine candidates that may soon become ripe for approval. But, in all fairness to the progress, tempering some of the excitement is warranted. There are two s...

NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Soligenix, Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, will be presenting at this year's virtual Fall Investor Summ...

Soligenix (SNGX): Q3 GAAP EPS of -$0.06 beats by $0.07.Revenue of $0.6M (-53.8% Y/Y) misses by $0.45M.Shares +0.59% PM.Press Release For further details see: Soligenix EPS beats by $0.07, misses on revenue

Soligenix Announces Recent Accomplishments And Third Quarter 2020 Financial Results PR Newswire PRINCETON, N.J., Nov. 12, 2020 PRINCETON, N.J. , Nov. 12, 2020 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biophar...

Additional data from Phase 3 Flash trial evaluating Soligenix's ([[SNGX]] +6.4%) SGX301 (synthetic hypericin) in patients with cutaneous T-cell lymphoma ((CTCL)), has reinforced positive primary endpoint treatment response demonstrated in treatment cycle 1, with further improved response...